All In Biotech

Drug Trial Radar · NCT06699836

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Actual

Start

Jun 16, 2025

Primary completion

Jan 2028

Study completion Mar 2028

Sponsor

Lead sponsor
CytoDyn, Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with MSS, mCRC who have progressed on prior treatment, with optional open label leronlimab plus pembrolizumab cohort for participants who have documented disease progression during the initial treatment period of the study and who continue to meet the initial inclusion and exclusion criteria. The main questions this study aims to answer are: 1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in participants with MSS, mCRC who have progressed on prior treatment before participating in the study. 2. In participants who have documented progressive disease during the initial treatment period of the study, what is the objective response rate when leronlimab is administered in combination with pembrolizumab. 3. Is leronlimab safe and well tolerated when used in combination with trifluridine and tipiracil+ bevacizumab or in combination with pembrolizumab.

Conditions

  • Metastatic Colorectal Cancer (mCRC)

Interventions

  • 350 mg leronlimabDrug

    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

  • 700 mg leronlimabDrug

    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

  • 200 mg pembrolizumabDrug

    Pembrolizumab is a humanized monoclonal antibody that binds to the programmed death receptor-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC.Time frame: From enrolment through end of treatment at 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California

  • Pacific Hematology Oncology Associates

    San Francisco, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Norton Cancer Institute, Brownsboro Hospital Campus

    Louisville, Kentucky

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Summit Cancer Center

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.